Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Ad26.ZEBOV and MVA-BN-Filo
NCT02661464Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2016
- Primary completion
- Dec 2021
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 7
01
Overview
A Phase 3 trial of zabdeno, Mvabea in Ebola virus disease (EVD), sponsored by Janssen Pharmaceutical. Started May 2016; status: terminated.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02661464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661464.